Shenzhen Neocura Biotechnology Corporation

Shenzhen Neocurna Biotechnology Corporation

Neocura Bio-medical Technology Co., Ltd

Beijing Neocurna Biotechnology Corporation

Ji Wan

Qi Song

Youdong Pan

Jian Wang

Gang Liu

Yi Tong Wang

Yiming Shen

Ying Wen

Jun-Yuan Huang

An Xiao

A method and a system for calculating tumor neoantigen burden (TNB) are provided. The method includes: step S: processing a normal sample and a tumor sample, sequencing a specific region and detecting somatic mutations in the sample; step S: annotating and filtering the somatic mutations, and translating to obtain mutant peptide sequences of a patient; step S: filtering the mutant peptide sequences to obtain neopeptide sequences based on a proteome of the normal sample; step S, performing a human leukocyte antigen (HLA) typing analysis based on alignment data of the normal sample to obtain HLA genotypes of the sample; step S, predicting binding affinities between the neopeptide sequences and the HLA genotypes to obtain specific neoantigens of the sample, and performing a weighted scoring on each of the specific neoantigens and calculating the TNB of the sample.

Method and system for calculating tumor neoantigen burden

A method and a platform for detecting an immunogenicity of a tumor neoantigen are provided. Specifically, the detection method includes the following steps: culturing human peripheral blood monocytes ex vivo for 13 days, adding an antigenic peptide fragment of human influenza virus and stimulating and activating cytokines, antigenic peptides, and immunoadjuvants during the 13 days, and finally conducting enzyme-linked immunospot (ELISPOT) chromogenic reaction and instrument-based scanning, counting, and analysis to detect the immunogenicity of tumor neoantigen. An application of the detection method and platform in biomedicine is provided. Compared with the prior art, the detection method and platform have advantages and characteristics of a short detection period, high convenience, low consumption of experimental cells, and low detection cost. Therefore, the detection method and platform can be used for ex vivo high-throughput assay for the immunogenicity of the tumor neoantigen.

Method and platform for detecting immunogenicity of tumor neoantigen

Growing community of inventors

Shenzhen, China

Ji Wan